MA49886A - Anticorps anti-par2 et leurs utilisations - Google Patents

Anticorps anti-par2 et leurs utilisations

Info

Publication number
MA49886A
MA49886A MA049886A MA49886A MA49886A MA 49886 A MA49886 A MA 49886A MA 049886 A MA049886 A MA 049886A MA 49886 A MA49886 A MA 49886A MA 49886 A MA49886 A MA 49886A
Authority
MA
Morocco
Prior art keywords
par2 antibodies
par2
antibodies
Prior art date
Application number
MA049886A
Other languages
English (en)
Inventor
Claire Dobson
David Fairman
Ian Gurrell
Philip Newton
Sadhana Podichetty
Peter Thornton
Richard Williams
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MA49886A publication Critical patent/MA49886A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MA049886A 2017-03-16 2018-03-16 Anticorps anti-par2 et leurs utilisations MA49886A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472462P 2017-03-16 2017-03-16
US201862637766P 2018-03-02 2018-03-02

Publications (1)

Publication Number Publication Date
MA49886A true MA49886A (fr) 2020-06-24

Family

ID=61827709

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049886A MA49886A (fr) 2017-03-16 2018-03-16 Anticorps anti-par2 et leurs utilisations

Country Status (30)

Country Link
US (4) US10836822B2 (fr)
EP (2) EP4681726A3 (fr)
JP (3) JP7222901B2 (fr)
KR (1) KR102711884B1 (fr)
CN (1) CN110446720B (fr)
AU (3) AU2018235031B2 (fr)
BR (1) BR112019018752A2 (fr)
CA (1) CA3055251A1 (fr)
CL (1) CL2019002626A1 (fr)
CO (1) CO2019010975A2 (fr)
CR (1) CR20190417A (fr)
DK (1) DK3596125T3 (fr)
ES (1) ES3056721T3 (fr)
FI (1) FI3596125T3 (fr)
HR (1) HRP20251643T1 (fr)
IL (1) IL269134B2 (fr)
LT (1) LT3596125T (fr)
MA (1) MA49886A (fr)
MX (1) MX2019010802A (fr)
NZ (1) NZ757915A (fr)
PH (1) PH12019502087A1 (fr)
PL (1) PL3596125T3 (fr)
PT (1) PT3596125T (fr)
RS (1) RS67581B1 (fr)
SG (1) SG11201908056QA (fr)
SI (1) SI3596125T1 (fr)
TW (1) TWI788332B (fr)
UA (1) UA125757C2 (fr)
WO (1) WO2018167322A1 (fr)
ZA (1) ZA201906004B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
SG10201509790YA (en) 2010-11-30 2015-12-30 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
WO2016098356A1 (fr) 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-c5 et leurs procédés d'utilisation
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN112142844B (zh) 2015-02-05 2025-07-25 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
JP7191833B2 (ja) 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用
UA125757C2 (uk) * 2017-03-16 2022-06-01 Медімм'Юн Лімітед Антитіло до par2 і його застосування
US12214216B1 (en) 2019-10-16 2025-02-04 Helen Feng Photon enhanced bone growth system and method
EP4200018B1 (fr) 2020-08-18 2025-01-01 Cephalon LLC Anticorps anti-par-2 et procédés d'utilisation associés
GB202204159D0 (en) 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies
AU2024212070A1 (en) 2023-01-25 2025-07-31 Medimmune Limited Migraine therapy
WO2025172573A1 (fr) 2024-02-16 2025-08-21 Domain Therapeutics Combinaisons d'inhibiteurs de par2 et d'inhibiteurs de points de contrôle immunitaires pour le traitement du cancer
WO2025191185A1 (fr) 2024-03-15 2025-09-18 Domain Therapeutics Composés à base d'azine utilisés en tant qu'inhibiteurs de par-2 et leurs utilisations thérapeutiques

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002248184C1 (en) 2000-12-12 2018-01-04 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
WO2004080373A2 (fr) * 2003-03-11 2004-09-23 Bayer Healthcare Ag Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 2 active par la proteinase (par2) couple aux proteines g
WO2005103081A2 (fr) 2004-04-20 2005-11-03 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
RU2430113C2 (ru) * 2004-11-04 2011-09-27 Тафтс Медикал Сентер, Инк. Химерный полипептид, селективно взаимодействующий с родственным ему рецептором хемокина, фармацевтическая композиция и применение химерного полипептида (варианты)
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
CL2008001887A1 (es) * 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
AR070911A1 (es) 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
CA2733041A1 (fr) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Effecteurs de l'activation par-2 et leur utilisation dans la modulation d'une inflammation
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
CN105218674A (zh) 2010-03-11 2016-01-06 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
TWI596115B (zh) * 2012-08-13 2017-08-21 再生元醫藥公司 具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體
CN106459192B (zh) 2014-06-30 2021-08-03 默克专利股份公司 具有pH依赖性抗原结合的抗TNFa抗体
UA125757C2 (uk) * 2017-03-16 2022-06-01 Медімм'Юн Лімітед Антитіло до par2 і його застосування

Also Published As

Publication number Publication date
SI3596125T1 (sl) 2026-01-30
EP3596125B1 (fr) 2025-11-19
JP2023055895A (ja) 2023-04-18
LT3596125T (lt) 2026-01-26
IL269134A (en) 2019-11-28
FI3596125T3 (fi) 2025-12-29
EP4681726A3 (fr) 2026-04-01
IL269134B2 (en) 2024-07-01
BR112019018752A2 (pt) 2020-05-05
DK3596125T3 (da) 2025-12-22
AU2021257983A1 (en) 2021-11-25
CN110446720B (zh) 2023-09-12
WO2018167322A1 (fr) 2018-09-20
NZ757915A (en) 2023-05-26
CR20190417A (es) 2019-12-06
AU2018235031A1 (en) 2019-10-31
AU2021257983B2 (en) 2025-02-27
AU2025203947A1 (en) 2025-06-19
MX2019010802A (es) 2019-10-30
JP7222901B2 (ja) 2023-02-15
CO2019010975A2 (es) 2019-10-21
ES3056721T3 (en) 2026-02-24
IL269134B1 (en) 2024-03-01
RS67581B1 (sr) 2026-01-30
US20180305450A1 (en) 2018-10-25
JP2025102812A (ja) 2025-07-08
US10836822B2 (en) 2020-11-17
AU2018235031B2 (en) 2021-08-12
EP4681726A2 (fr) 2026-01-21
PL3596125T3 (pl) 2026-02-09
US20230242639A1 (en) 2023-08-03
UA125757C2 (uk) 2022-06-01
CL2019002626A1 (es) 2019-12-06
TW201843176A (zh) 2018-12-16
ZA201906004B (en) 2025-10-29
HRP20251643T1 (hr) 2026-02-13
AU2025203947A9 (en) 2026-03-19
PT3596125T (pt) 2025-11-27
EP3596125A1 (fr) 2020-01-22
PH12019502087A1 (en) 2020-03-09
JP2020509762A (ja) 2020-04-02
KR20190129925A (ko) 2019-11-20
SG11201908056QA (en) 2019-09-27
TWI788332B (zh) 2023-01-01
KR102711884B1 (ko) 2024-10-02
CN110446720A (zh) 2019-11-12
US11591389B2 (en) 2023-02-28
CA3055251A1 (fr) 2018-09-20
US20210061905A1 (en) 2021-03-04
US20260078180A1 (en) 2026-03-19

Similar Documents

Publication Publication Date Title
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3891183A4 (fr) Anticorps anti-claudine et leurs utilisations
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
MA49683A (fr) Anticorps anti-cd8 et leurs utilisations
EP3504243A4 (fr) Anticorps anti-tim-3 et leurs utilisations
EP3661965A4 (fr) Anticorps anti-cd47 et leurs utilisations
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3645563A4 (fr) Anticorps anti-fam19a5 et leurs utilisations
EP3283516A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3733702A4 (fr) Anticorps anti-lag-3 et utilisations associées
EP3790586A4 (fr) Anticorps anti-dll3 et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
EP3672987A4 (fr) Anticorps anti-apéline et leurs utilisations
EP3661555A4 (fr) Anticorps bispécifiques et leurs utilisations